GH Research PLC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Accelerated filerEmerging growth company
State of Incorporation
Ireland
Business Address
JOSHUA DAWSON HOUSE, DUBLIN 2, L2, D02 RY95
Mailing Address
JOSHUA DAWSON HOUSE, DUBLIN 2, L2, D02 RY95
Phone
353 1 437 8334
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | April 2, 2026 | View on SEC |
| 3 Initial insider ownership report | April 2, 2026 | View on SEC |
| 3 Initial insider ownership report | April 2, 2026 | View on SEC |
| 3 Initial insider ownership report | April 2, 2026 | View on SEC |
| 3 Initial insider ownership report | April 2, 2026 | View on SEC |
| 3 Initial insider ownership report | April 2, 2026 | View on SEC |
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 6-K Foreign company current report | March 25, 2026 | View on SEC |
| 6-K Foreign company current report | March 16, 2026 | View on SEC |
| 6-K Foreign company current report | March 5, 2026 | View on SEC |
Annual Reports
20-F
March 5, 2026
- GH Research PLC is a clinical-stage biopharmaceutical company developing novel psychedelic-based therapies.
- Its lead product, GH001 (inhaled 5-MeO-DMT), is in Phase 2b clinical trials for treatment-resistant depression (TRD) and aims for rapid, sustained antidepressant effects.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.